Prognostic value of p53 and MIB‐1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement

Frank, Igor; Cheville, John C.; Blute, Michael L.; Lohse, Mariah; Karnes, R. Jeffrey; Weaver, Amy L.; Sebo, Thomas J.; Nehra, Ajay; Zincke, Horst

doi:10.1002/cncr.20567

Cited by 24 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumors with a high Ki-67 LI are frequently more aggressive than those with low Ki-67 LI 28. In addition, factors involved in angiogenesis such as VEGF are associated with tumor growth and metastasis 17-19.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma

Saad

Yeap

Thunnissen

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND. To the authors' knowledge, there are no reliable markers able to identify patients with nonsmall cell lung cancer (NSCLC) that will develop metastases to the brain. The authors investigated associations between immunohistochemical markers and the development of brain metastases in patients with NSCLC. METHODS. This was a hospital‐based, case‐control study of patients who were newly diagnosed with NSCLC between 1989 and 2003, developed brain metastases, and had pathology material available from both the primary NSCLC and the brain metastases. These patients were compared with a control group of patients who had NSCLC and no evidence of brain metastases. NSCLC was examined for expression levels of Ki‐67, caspase‐3, vascular endothelial growth factor A (VEGF‐A), VEGF‐C, E‐cadherin, and epidermal growth factor receptor (EGFR) in 54 surgical pathology specimens using immunohistochemistry, and associations were evaluated between those markers and the development of brain metastases. RESULTS. Brain metastases developed after a median of 12.5 months (range, 1.7‐89.4 months) after the diagnosis of NSCLC. A significantly increased risk of developing brain metastases was associated with patients with NSCLC who had primary tumors with high Ki‐67 levels (adjusted odds ratio [OR] of 12.2; 95% confidence interval [95% CI], 2.4‐70.4 [P < .001]), low caspase‐3 expression (adjusted OR of 43; 95% CI, 5.3 to >100 [P < .001]), high VEGF‐C expression (adjusted OR of 14.6; 95% CI, 2.0 to >100 [P < .001]), and low E‐cadherin (adjusted OR of 3.6; 95% CI, 0.9‐16.4 [P = .05]). No significant risk was associated with VEGF‐A or EGFR expression. High Ki‐67 expression also was associated with a shorter overall survival (P = .04). CONCLUSIONS. The results of the current study indicated that patients with NSCLC who had high Ki‐67 expression, low caspase‐3 expression, high VEGF‐C expression, and low E‐cadherin expression in their tumors may benefit from close surveillance because they may have an increased risk of developing brain metastases. Cancer 2008. © 2008 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma

Saad

Yeap

Thunnissen

et al. 2008

Cancer

View full text Add to dashboard Cite

show abstract

“…However, most patients in that series had locally advanced or node-positive disease. Frank et al (14) examined the expression of Ki-67 in the lymph node metastases from 139 patients who underwent cystectomy for TCC at their institution and found no association between Ki-67 and disease-related outcomes.…”

Section: Discussionmentioning

confidence: 99%

Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease

Margulis¹,

Shariat²,

Ashfaq

et al. 2006

Clinical Cancer Research

145

View full text Add to dashboard Cite

Purpose: To determine the association of the cell proliferative marker Ki-67 with pathologic features and disease prognosis in patients with transitional cell carcinoma (TCC) of the urinary bladder. Methods: Immunohistochemical staining for Ki-67 was done on serial cuts from tissue microarrays containing cystectomy specimens from 9 patients without bladder cancer and 226 consecutive patients with bladder TCC. We also assessed malignant lymph nodes from 50 of the 226 cystectomy patients. Results: Ki-67 expression was increased in 42.5% cystectomy specimens and in 54% metastatic lymph nodes. In contrast, it was absent in all nine benign cystectomy specimens. Ki-67 overexpression was associated with advanced pathologic stage, higher grade, lymphovascular invasion, and metastases to lymph nodes (P = 0.001, 0.040, 0.031, and 0.036, respectively). In multivariate analyses, pathologic stage and lymph node metastases were independent predictors of disease recurrence and bladder cancer-specific mortality. In the subgroup of patients with organ-confined disease (

show abstract

“…This might be especially true in patients with PUNLMP and NILGC, whereas Aurora-A staining seems to be less useful in NIHGC and Cis. Several authors have shown implication of Aurora-A in carcinogenesis, demonstrating overexpression in human gastric carcinoma cell lines, primary gastric carcinoma and hepatocellular carcinoma [4,10,11,14,25]. As a matter of fact, Aurora-A regulates spindle cell assembly in mitosis and interferes in centrosome maturation.…”

Section: Discussionmentioning

confidence: 99%

Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms

et al. 2007

View full text Add to dashboard Cite

Aurora-A, a member of serine/threonine kinase, is implied in mitosis and centrosome maturation. Increasing levels of Aurora-A have been shown to be present in several malignancies and especially in bladder cancer. No immunohistochemical marker has shown to be able to predict the clinical outcome of patients with superficial bladder cancer, except MIB-1, as a predictive marker of relapse and progression. The aim was to investigate the expression of Aurora-A and MIB-1 in tissue micro arrays of superficial bladder cancer representative of pTa papillary urothelial neoplasm with different degrees of aggressiveness (low malignant potential [PUNLMP], non-invasive papillary urothelial carcinoma low grade [NILGC], non-invasive papillary urothelial carcinoma high grade [NIHGC] and carcinoma in situ). We analysed predictive values of both markers, their specificity and sensitivity in tumor recurrence. Aurora-A was a sensitive marker to predict tumor recurrence especially for pTa (PUNLMP, NILGC; PUNLMP p<0.001, NILGC p<0.001) with statistical significant correlation between immunohistochemical staining and clinical outcome. MIB-1 expression displayed statistical difference p=0.002 in the PUNLMP group and p=0.03 in the NILGC group. Aurora-A is a more sensitive marker than MIB-1 to predict relapse in pTa bladder neoplasias. The combination of both markers seems to have a very powerful predictive value of recurrence (p<0.001).

show abstract

Prognostic value of p53 and MIB‐1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement

Cited by 24 publications

References 27 publications

Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma

Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma

Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease

Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms

Contact Info

Product

Resources

About